{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T12:56:44Z","timestamp":1754398604418,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T00:00:00Z","timestamp":1559952000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T00:00:00Z","timestamp":1559952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s13730-019-00405-4","type":"journal-article","created":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T15:02:23Z","timestamp":1560006143000},"page":"266-270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Atypical reduction of plasma ADAMTS13 activity by a non-IgG-type inhibitor in a patient with hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli"],"prefix":"10.1007","volume":"8","author":[{"given":"Shinya","family":"Nakayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuma","family":"Hirashio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Yorishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4271-9964","authenticated-orcid":false,"given":"Takao","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,8]]},"reference":[{"key":"405_CR1","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","volume":"339","author":"M Furlan","year":"1998","unstructured":"Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, L\u00e4mmle B. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578\u201384.","journal-title":"N Engl J Med"},{"key":"405_CR2","doi-asserted-by":"publisher","first-page":"e9895","DOI":"10.1097\/MD.0000000000009895","volume":"97","author":"V Birlutiu","year":"2018","unstructured":"Birlutiu V, Birlutiu RM. Haemolytic-uremic syndrome due to infection with adenovirus: a case report and literature review. Medicine. 2018;97:e9895.","journal-title":"Medicine."},{"key":"405_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJM199108083250604","volume":"325","author":"GA Rock","year":"1991","unstructured":"Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325:393\u20137.","journal-title":"N Engl J Med"},{"key":"405_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1182\/blood-2003-01-0193","volume":"102","author":"SK Vesely","year":"2003","unstructured":"Vesely SK, George JN, L\u00e4mmle B, Studt JD, Alberio L, El-Harake MA, Raskob GE. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102:60\u20138.","journal-title":"Blood"},{"issue":"8325","key":"405_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0140-6736(83)91795-6","volume":"1","author":"MA Karmali","year":"1983","unstructured":"Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet. 1983;1(8325):619\u201320.","journal-title":"Lancet"},{"key":"405_CR6","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nrneph.2012.196","volume":"8","author":"H Trachtman","year":"2012","unstructured":"Trachtman H, Austin C, Lewinski M, Stahl RAK. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol. 2012;8:658\u201369.","journal-title":"Nat Rev Nephrol."},{"key":"405_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/MNH.0b013e328354a62e","volume":"21","author":"TN Petruzziello-Pellegrini","year":"2012","unstructured":"Petruzziello-Pellegrini TN, Marsden PA. Shiga toxin-associated hemolytic uremic syndrome: advance in pathogenesis and therapeutics. Curr Opin Nephrol Hypertens. 2012;21:433\u201340.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"405_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1086\/318514","volume":"32","author":"RL Guerrant","year":"2001","unstructured":"Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV, Hennessy T, Griffin PM, DuPont H, Sack RB, Tarr P, Neill M, Nachamkin I, Reller LB, Osterholm MT, Bennish ML, Pickering LK, Infectious Diseases Society of America. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis. 2001;32:331\u201351.","journal-title":"Clin Infect Dis."},{"key":"405_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1056\/NEJMcp031534","volume":"350","author":"NM Thielman","year":"2004","unstructured":"Thielman NM, Guerrant RL. Clinical practice. Acute infectious diarrhea. N Engl J Med. 2004;350:38\u201347.","journal-title":"N Engl J Med."},{"key":"405_CR10","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/archpediatrics.2011.152","volume":"165","author":"CA Hickey","year":"2011","unstructured":"Hickey CA, Beattie TJ, Cowieson J, Miyashita Y, Strife CF, Frem JC, Peterson JM, Butani L, Jones DP, Havens PL, Patel HP, Wong CS, Andreoli SP, Rothbaum RJ, Beck AM, Tarr PI. Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med. 2011;165:884\u20139.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"405_CR11","doi-asserted-by":"publisher","first-page":"e0124655","DOI":"10.1371\/journal.pone.0124655","volume":"10","author":"Y Yoshida","year":"2015","unstructured":"Yoshida Y, Miyata T, Matsumoto M, Shirotani-Ikejima H, Uchida Y, Ohyama Y, Kokubo T, Fujimura Y. A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan. PLoS One. 2015;10:e0124655.","journal-title":"PLoS One"},{"key":"405_CR12","doi-asserted-by":"publisher","first-page":"e4104","DOI":"10.1097\/MD.0000000000004104","volume":"95","author":"T Omura","year":"2016","unstructured":"Omura T, Watanabe E, Otsuka Y, Yoshida Y, Kato H, Nangaku M, Miyata T, Oda S. Complete remission of thrombotic microangiopathy after treatment with eculizumab in a patient with non-Shiga toxin-associated bacterial enteritis: a case report. Medicine (Baltimore). 2016;95:e4104.","journal-title":"Medicine (Baltimore)."},{"key":"405_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/(SICI)1096-8652(199604)51:4<255::AID-AJH1>3.0.CO;2-V","volume":"51","author":"H Wada","year":"1996","unstructured":"Wada H, Wakita Y, Nakase T, Shimura M, Hiyoyama K, Nagaya S, Deguchi H, Mori Y, Kaneko T, Deguchi K, Fujii J, Shiku H. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am J Hematol. 1996;51:255\u201360.","journal-title":"Am J Hematol"},{"key":"405_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","volume":"158","author":"M Scully","year":"2012","unstructured":"Scully M, Hunt BJ, Benjamin S. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158:323\u201335.","journal-title":"Br J Haematol"},{"key":"405_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2169\/internalmedicine.49.2706","volume":"49","author":"Y Fujimura","year":"2010","unstructured":"Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998\u20132008. Intern Med. 2010;49:7\u201315.","journal-title":"Intern Med"},{"key":"405_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.blre.2014.07.004","volume":"28","author":"FC Verbij","year":"2014","unstructured":"Verbij FC, Fijnheer R, Voorberg J, Sorvillo N. Acquired TTP: ADAMTS13 meets the immune system. Blood Rev. 2014;28:227\u201334.","journal-title":"Blood Rev"},{"key":"405_CR17","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/ndt\/gfq021","volume":"25","author":"ME Knecht","year":"2010","unstructured":"Knecht ME, Mayr M, Ferrari S, Scheiflinger F, Trendelenburg M. A patient with SLE-associated thrombotic microangiopathy and non-neutralizing antibodies against ADAMTS13. Nephrol Dial Transplant. 2010;25:1720\u20132.","journal-title":"Nephrol Dial Transplant"},{"key":"405_CR18","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1056\/NEJMcp053024","volume":"354","author":"JN George","year":"2006","unstructured":"George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med. 2006;354:1927\u201335.","journal-title":"N Engl J Med."}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-019-00405-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13730-019-00405-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-019-00405-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T23:22:47Z","timestamp":1591485767000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13730-019-00405-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,8]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["405"],"URL":"https:\/\/doi.org\/10.1007\/s13730-019-00405-4","relation":{},"ISSN":["2192-4449"],"issn-type":[{"type":"electronic","value":"2192-4449"}],"subject":[],"published":{"date-parts":[[2019,6,8]]},"assertion":[{"value":"28 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All the authors have declared no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee at which the studies were conducted (IRB approval number Hi-204) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}